Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sven Rottenberg

Showing results (121-130 of 122) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 122 results.
Nature|August 10, 2022
Truncated FGFR2 is a clinically actionable oncogene in multiple cancersDaniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, et al.
The Lancet. Oncology|June 29, 2026
Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trialRianne L Seefat, Sonja B Vliek, Vincent M T de Jong, et al.
Pageof 13

Showing results (121-130 of 122) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 122 results.
Nature|August 10, 2022
Truncated FGFR2 is a clinically actionable oncogene in multiple cancersDaniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, et al.
The Lancet. Oncology|June 29, 2026
Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trialRianne L Seefat, Sonja B Vliek, Vincent M T de Jong, et al.
Pageof 13